Scarica l'app Stockscreener
0.0949
19.37%
-0.0228
Dopo l'orario di chiusura:
.09
-0.0049
-5.16%
AIM ImmunoTech Inc Borsa (AIM) Ultime notizie
NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire
Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - Benzinga
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call Transcript - Insider Monkey
AIM ImmunoTech’s Earnings Call: Progress Amid Challenges - TipRanks
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strat - GuruFocus
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire
AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Preview For AIM ImmunoTech - Benzinga
AIM ImmunoTech Inc. (AIM) reports earnings - Quartz
AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com
AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq
AIM ImmunoTech's 5 Game-Changing Programs: Pancreatic Cancer Trial Leads 2025 Strategy - StockTitan
Aim Immunotech CEO Thomas Equels buys $6,730 in stock By Investing.com - Investing.com Canada
Aim Immunotech CEO Thomas Equels buys $6,730 in stock - Investing.com India
What is AIM ImmunoTech Inc (AIM) Stock Return on Shareholders’ Capital? - SETE News
Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com India
Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock By Investing.com - Investing.com Australia
Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock - Investing.com India
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
AIM ImmunoTech appoints Chemerow as an Independent Director - MSN
AIM ImmunoTech Inc. Appoints Principal Investigator for Clinical Study Combining Ampligen and AstraZeneca's FluMist for Influenza Vaccine Development - Nasdaq
AIM announces Paul Goepfert, MD, as the principal - GlobeNewswire
Could This $10M Avian Flu Vaccine Strategy Outperform Billion-Dollar mRNA Alternatives? - StockTitan
AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City - ACCESS Newswire
AIM ImmunoTech to Present at the Investor Summit in Philadelphia - ACCESS Newswire
AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM' - ACCESS Newswire
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
AIM ImmunoTech Plans to Meet NYSE Compliance by 2026 Amid Cancer and Antiviral Drug Advances - HPBL
AIM ImmunoTech Eyes a Resilient Comeback with Strategic Moves to Stay Afloat - Smartphone Magazine
AIM ImmunoTech gains NYSE compliance plan approval By Investing.com - Investing.com South Africa
Biotech Trailblazer AIM ImmunoTech Charts a Resilient Path to Equity Compliance - Jomfruland.net
AIM ImmunoTech gains NYSE compliance plan approval - Investing.com
AIM ImmunoTech Secures NYSE American Compliance Plan Approval – What It Means for Investors - HPBL
AIM ImmunoTech Says NYSE American Accepts Plan to Regain Compliance -February 26, 2025 at 01:37 pm EST - Marketscreener.com
AIM ImmunoTech Inc. Receives Approval from NYSE American for Compliance Plan with Listing Standards - Nasdaq
Can AIM ImmunoTech Maintain NYSE Listing? Exchange Grants Rare 2-Year Extension - StockTitan
AIM ImmunoTech Appoints David Chemerow to Board - TipRanks
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - The Manila Times
Can This Former Comscore Executive Turn Around AIM ImmunoTech's Immuno-Pharma Ambitions? - StockTitan
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):